search
Back to results

Anticoagulation Post Laparoscopic Splenectomy

Primary Purpose

Portal Vein Thrombosis, Splenic Vein Thrombosis

Status
Terminated
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Enoxaparin
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Portal Vein Thrombosis focused on measuring anticoagulation, thrombosis, portal vein thrombosis, splenic vein thrombosis, splenectomy, randomized, laparoscopic splenectomy, lovenox

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Scheduled to undergo laparoscopic splenectomy at The University of Alberta or Grey Nun's Community Hospitals
  • Capable of understanding the purpose and risks of the study and willing/able to sign a statement of informed consent
  • Willing to undergo daily subcutaneous injections of Lovenox®

Exclusion Criteria:

  • Pregnant or nursing
  • Unable or unwilling to provide informed consent
  • Bleeding diathesis or currently on anticoagulation therapy (i.e. coumadin, heparin, LMWH)
  • Hemorrhagic cerebral vascular accident
  • Severe uncontrolled hypertension
  • Diabetic or hemorrhagic retinopathy
  • Contradictions to anticoagulation (i.e. active GI bleed, gastric or duodenal ulcer, sustained platelet count < 50 x103/uL, splenectomy due to trauma or history of heparin induced thrombocytopenia)
  • Conversion to open splenectomy
  • Allergy to Lovenox®, heparin, or other low molecular weight heparins
  • Bacterial endocarditis

Sites / Locations

  • University of Alberta Hospital
  • Grey Nuns Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Lovenox

No Lovenox

Arm Description

Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy

Patients do NOT receive Lovenox post laparoscopic splenectomy

Outcomes

Primary Outcome Measures

The incidence of portal/splenic vein thrombosis post laparoscopic splenectomy

Secondary Outcome Measures

Full Information

First Posted
October 8, 2008
Last Updated
June 23, 2009
Sponsor
University of Alberta
Collaborators
Edmonton Civic Employees Research Fund, Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00769873
Brief Title
Anticoagulation Post Laparoscopic Splenectomy
Official Title
Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698
Study Type
Interventional

2. Study Status

Record Verification Date
June 2009
Overall Recruitment Status
Terminated
Why Stopped
Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.
Study Start Date
October 2006 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
May 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Alberta
Collaborators
Edmonton Civic Employees Research Fund, Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Splenic/portal vein thrombosis is an alarming complication of splenectomy. Retrospective studies in the literature have shown the incidence of symptomatic splenic/portal vein thrombosis to be between 0.7% (Rattner et al., 1993) to 8% (Winslow et al., 2002). This is a single-center, prospective, randomized study in subjects undergoing laparoscopic splenectomy. All participants will receive one dose of pre-operative low molecular weight heparin (Lovenox®) subcutaneously, 2 hours prior to surgery. Participants will be randomized pre-operatively to treatment or control group however the treatment allocation will not be revealed until the surgery is complete. Postoperatively, those assigned to the treatment group will receive 40 mg of Lovenox® subcutaneously once a day for 21 days; those in the control group will not. Patients with severe renal impairment will receive an adjusted dose of Lovenox® (30 mg subcutaneous dose daily). All patients will have a baseline abdominal Doppler ultrasound preoperatively and a second one done at 14 to 28 days post surgery to monitor for the presence of portal vein and/or splenic vein thrombosis. They will also have their lipase and liver function tests checked to correlate with the imaging findings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Portal Vein Thrombosis, Splenic Vein Thrombosis
Keywords
anticoagulation, thrombosis, portal vein thrombosis, splenic vein thrombosis, splenectomy, randomized, laparoscopic splenectomy, lovenox

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
35 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lovenox
Arm Type
Active Comparator
Arm Description
Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy
Arm Title
No Lovenox
Arm Type
No Intervention
Arm Description
Patients do NOT receive Lovenox post laparoscopic splenectomy
Intervention Type
Drug
Intervention Name(s)
Enoxaparin
Other Intervention Name(s)
Low molecular weight heparin
Intervention Description
Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days
Primary Outcome Measure Information:
Title
The incidence of portal/splenic vein thrombosis post laparoscopic splenectomy
Time Frame
three years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Scheduled to undergo laparoscopic splenectomy at The University of Alberta or Grey Nun's Community Hospitals Capable of understanding the purpose and risks of the study and willing/able to sign a statement of informed consent Willing to undergo daily subcutaneous injections of Lovenox® Exclusion Criteria: Pregnant or nursing Unable or unwilling to provide informed consent Bleeding diathesis or currently on anticoagulation therapy (i.e. coumadin, heparin, LMWH) Hemorrhagic cerebral vascular accident Severe uncontrolled hypertension Diabetic or hemorrhagic retinopathy Contradictions to anticoagulation (i.e. active GI bleed, gastric or duodenal ulcer, sustained platelet count < 50 x103/uL, splenectomy due to trauma or history of heparin induced thrombocytopenia) Conversion to open splenectomy Allergy to Lovenox®, heparin, or other low molecular weight heparins Bacterial endocarditis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Shapiro, MD PhD FRCS(Eng)
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Haili Wang, MD FRCSC
Organizational Affiliation
University of Alberta
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Daniel Kopac, MD MSc
Organizational Affiliation
University of Alberta
Official's Role
Study Director
Facility Information:
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
Grey Nuns Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6L 5X8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
11919306
Citation
Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 Mar 28;346(13):975-80. doi: 10.1056/NEJMoa012385.
Results Reference
background
PubMed Identifier
15286956
Citation
Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg. 2004 Aug;91(8):965-74. doi: 10.1002/bjs.4639.
Results Reference
background
PubMed Identifier
9747171
Citation
Chaffanjon PC, Brichon PY, Ranchoup Y, Gressin R, Sotto JJ. Portal vein thrombosis following splenectomy for hematologic disease: prospective study with Doppler color flow imaging. World J Surg. 1998 Oct;22(10):1082-6. doi: 10.1007/s002689900521.
Results Reference
background
PubMed Identifier
9278651
Citation
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997 Aug;84(8):1099-103.
Results Reference
background
PubMed Identifier
14627254
Citation
Fujita F, Lyass S, Otsuka K, Giordano L, Rosenbaum DL, Khalili TM, Phillips EH. Portal vein thrombosis following splenectomy: identification of risk factors. Am Surg. 2003 Nov;69(11):951-6.
Results Reference
background
PubMed Identifier
15383478
Citation
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.
Results Reference
background
PubMed Identifier
11442521
Citation
Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001 Jul;88(7):913-30. doi: 10.1046/j.0007-1323.2001.01800.x.
Results Reference
background
PubMed Identifier
8259430
Citation
Petit P, Bret PM, Atri M, Hreno A, Casola G, Gianfelice D. Splenic vein thrombosis after splenectomy: frequency and role of imaging. Radiology. 1994 Jan;190(1):65-8. doi: 10.1148/radiology.190.1.8259430.
Results Reference
background
PubMed Identifier
10971433
Citation
van't Riet M, Burger JW, van Muiswinkel JM, Kazemier G, Schipperus MR, Bonjer HJ. Diagnosis and treatment of portal vein thrombosis following splenectomy. Br J Surg. 2000 Sep;87(9):1229-33. doi: 10.1046/j.1365-2168.2000.01514.x.
Results Reference
background

Learn more about this trial

Anticoagulation Post Laparoscopic Splenectomy

We'll reach out to this number within 24 hrs